Semaglutide
Also known as GLP-1 analog
GLP-1 receptor agonist
The most widely studied single-receptor incretin analog, examined for appetite regulation, glycemic control and body weight.
How it works
Binds the GLP-1 receptor in the pancreas, gut and hypothalamus, slowing gastric emptying and enhancing glucose-dependent insulin release while reducing hunger signaling.
What research has shown
Phase 3 literature reports mean weight reductions near 15% at 68 weeks and HbA1c reductions around 1.5 to 1.8%.
Reported ranges in the literature
Low end
0.25 mg weekly (4-week initiation step)
Optimal
0.5 to 1.7 mg weekly after stepwise titration
High end
2.4 mg weekly, the ceiling used in weight-management trials
Frequency reported in the literature: Once weekly. Note: Trial protocols titrate in 4-week steps to limit gastrointestinal effects.
Protocol duration and pairing
Typical study duration
68 week protocols are standard in weight-management trials; glycemic trials run 40 to 104 weeks.
Best paired with
The cagrilintide plus semaglutide combination is the most studied pairing in this class.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.